159 related articles for article (PubMed ID: 36708555)
21. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
Stomper J; Meier R; Ma T; Pfeifer D; Ihorst G; Blagitko-Dorfs N; Greve G; Zimmer D; Platzbecker U; Hagemeijer A; Schmitt-Graeff I; Lübbert M
Clin Epigenetics; 2021 Apr; 13(1):77. PubMed ID: 33845873
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
23. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML.
Paul TA; Bies J; Small D; Wolff L
Blood; 2010 Apr; 115(15):3098-108. PubMed ID: 20190193
[TBL] [Abstract][Full Text] [Related]
24. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.
Tanaka S; Miyagi S; Sashida G; Chiba T; Yuan J; Mochizuki-Kashio M; Suzuki Y; Sugano S; Nakaseko C; Yokote K; Koseki H; Iwama A
Blood; 2012 Aug; 120(5):1107-17. PubMed ID: 22677129
[TBL] [Abstract][Full Text] [Related]
25. Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells
Al-Ghabkari A; Narendran A
Cancer Biol Ther; 2021 Apr; 22(4):333-344. PubMed ID: 33978549
[TBL] [Abstract][Full Text] [Related]
26. Tanshinone I, a new EZH2 inhibitor restricts normal and malignant hematopoiesis through upregulation of
Huang Y; Yu SH; Zhen WX; Cheng T; Wang D; Lin JB; Wu YH; Wang YF; Chen Y; Shu LP; Wang Y; Sun XJ; Zhou Y; Yang F; Hsu CH; Xu PF
Theranostics; 2021; 11(14):6891-6904. PubMed ID: 34093860
[No Abstract] [Full Text] [Related]
27. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
[TBL] [Abstract][Full Text] [Related]
28. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
[TBL] [Abstract][Full Text] [Related]
29. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
[TBL] [Abstract][Full Text] [Related]
30. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
31. EZH2 can be used as a therapeutic agent for inhibiting endothelial dysfunction.
Sun L; Li X; Luo H; Guo H; Zhang J; Chen Z; Lin F; Zhao G
Biochem Pharmacol; 2023 Jul; 213():115594. PubMed ID: 37207700
[TBL] [Abstract][Full Text] [Related]
32. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
Aldana J; Gardner ML; Freitas MA
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
[TBL] [Abstract][Full Text] [Related]
33. Gestational diabetes mellitus impairs fetal endothelial cell functions through a mechanism involving microRNA-101 and histone methyltransferase enhancer of zester homolog-2.
Floris I; Descamps B; Vardeu A; Mitić T; Posadino AM; Shantikumar S; Sala-Newby G; Capobianco G; Mangialardi G; Howard L; Dessole S; Urrutia R; Pintus G; Emanueli C
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):664-74. PubMed ID: 25614281
[TBL] [Abstract][Full Text] [Related]
34. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
35. EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.
Wang X; Dai H; Wang Q; Wang Q; Xu Y; Wang Y; Sun A; Ruan J; Chen S; Wu D
PLoS One; 2013; 8(4):e61341. PubMed ID: 23613835
[TBL] [Abstract][Full Text] [Related]
36. Regulation of histone methylation by automethylation of PRC2.
Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
[TBL] [Abstract][Full Text] [Related]
37. Role of EZH2 in bone marrow mesenchymal stem cells and immune-cancer interactions.
Liu Z; Jia Y; Guo Y; Wang H; Fu R
Crit Rev Oncol Hematol; 2022 Jan; 169():103547. PubMed ID: 34843930
[TBL] [Abstract][Full Text] [Related]
38. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
39. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
40. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
Ott M; Litzenburger UM; Sahm F; Rauschenbach KJ; Tudoran R; Hartmann C; Marquez VE; von Deimling A; Wick W; Platten M
PLoS One; 2012; 7(10):e47663. PubMed ID: 23077658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
